← SynDRA
ALTIRATINIB
SynDRA canonical compound SYN0038285 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | KDR | MET | TEK |
|---|
| Mechanism of action | MET inhibitor | VEGFR inhibitor |
|---|
All known targets
- KDR
- MET
- TEK
- NTRK1
- NTRK2
- NTRK3
Mechanisms of action (all sources)
- MET INHIBITOR
- Hepatocyte growth factor receptor inhibitor
- TEK INHIBITOR
- Tyrosine-protein kinase TIE-2 inhibitor
- KDR INHIBITOR
- Vascular endothelial growth factor receptor 2 inhibitor
- NTRK1 INHIBITOR
- Neurotrophic tyrosine kinase receptor inhibitor
- NTRK2 INHIBITOR
- NTRK3 INHIBITOR
- VEGFR inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- DCC-2701
- DP-5164
- T678746713
- altiratinibum
- RefChem:111601
- Altiratinib [USAN]
- MFCD28900672
- Altiratinib (USAN)
- DCC2701
- UNII-T678746713
- Altiratinib;DCC2701
- ALTIRATINIB [INN]
- Altiratinib(DCC-2701)
- Altiratinib(DCC-2701)?
- ALTIRATINIB [WHO-DD]
- SCHEMBL139906
- GTPL9174
- orb1306623
- SCHEMBL29358783
- SCHEMBL30128694
- SCHEMBL30337737
- DCC-270
- EX-A902
- C26H21F3N4O4
- GNNDEPIMDAZHRQ-UHFFFAOYSA-N
- GLXC-90229
- HY-B0791
- BDBM50193395
- NSC784590
- s6412
- AKOS026750329
- CS-3944
- NSC-784590
- SB18876
- NCGC00480913-04
- AC-35383
- FA137645
- MS-29472
- A4777
Look up ALTIRATINIB in the interactive SynDRA portal →